Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353(2), 172–187 (2005).
  Medline CASGoogle Scholar
• 2 Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2(2), 127–137 (2001).
  Medline CASGoogle Scholar
• 3 Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64(19), 6892–6899 (2004).
  Medline CASGoogle Scholar
• 4 Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19(3), 183–232 (1995).
  Medline CASGoogle Scholar
• 5 Moscatello DK, Holgado-Madruga M, Godwin AK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55(23), 5536–5539 (1995).
  Medline CASGoogle Scholar
• 6 Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7(3), 169–181 (2007). •Describes the results of genetic, biochemical and clinical studies focused on somatic mutations of EGFR that are related to EGFR-targeted therapies.
  Medline CASGoogle Scholar
• 7 Hynes NE, Macdonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 21(2), 177–184 (2009).
  Medline CASGoogle Scholar
• 8 Weinstein IB. Cancer. Addiction to oncogenes – the Achilles heal of cancer. Science 297(5578), 63–64 (2002).
  Medline CASGoogle Scholar
• 9 Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242(4880), 933–935 (1988).
  Medline CASGoogle Scholar
• 10 Fry DW, Kraker AJ, Mcmichael A et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265(5175), 1093–1095 (1994).
  Medline CASGoogle Scholar
• 11 Wakeling AE, Guy SP, Woodburn JR et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62(20), 5749–5754 (2002).
  Medline CASGoogle Scholar
• 12 Moyer JD, Barbacci EG, Iwata KK et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57(21), 4838–4848 (1997).
  Medline CASGoogle Scholar
• 13 Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34), 4702–4711 (2008).
  Medline CASGoogle Scholar
• 14 Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 21(12), 2237–2246 (2003).
  Medline CASGoogle Scholar
• 15 Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA 290(16), 2149–2158 (2003).
  Medline CASGoogle Scholar
• 16 Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22(16), 3238–3247 (2004).
  Medline CASGoogle Scholar
• 17 Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129–2139 (2004).
  Medline CASGoogle Scholar
• 18 Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497–1500 (2004).
  Medline CASGoogle Scholar
• 19 Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101(36), 13306–13311 (2004).
  Medline CASGoogle Scholar
• 20 Jackman D, Pao W, Riely GJ et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 28(2), 357–360 (2010).
  Medline CASGoogle Scholar
• 21 Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352(8), 786–792 (2005). •• Discovers T790M EGFR mutation in patients who received gefitinib treatment and relapsed.
  Medline CASGoogle Scholar
• 22 Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), e73 (2005). •• Discovers T790M EGFR mutation in patients who received gefitinib or erlotinib treatment and relapsed.
  MedlineGoogle Scholar
• 23 Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10(4), 307–317 (2011).
  Medline CASGoogle Scholar
• 24 Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9(1), 28–39 (2009).
  MedlineGoogle Scholar
• 25 Rabindran SK, Discafani CM, Rosfjord EC et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64(11), 3958–3965 (2004).
  Medline CASGoogle Scholar
• 26 Engelman JA, Zejnullahu K, Gale CM et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67(24), 11924–11932 (2007).
  Medline CASGoogle Scholar
• 27 Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10(11), 760–774 (2010). •• Describes rational treatment strategies for NSCLC harboring EGFR mutations based on biological studies.
  Medline CASGoogle Scholar
• 28 Juchum M, Gunther M, Laufer SA. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. Drug Resist. Update 20, 12–28 (2015).
  MedlineGoogle Scholar
• 29 Yun CH, Boggon TJ, Li YQ et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11(3), 217–227 (2007). • Discusses the drug senstivity of activating EGFR mutations by biochemical and structural analysis.
  Medline CASGoogle Scholar
• 30 Eck MJ, Yun CH. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small-cell lung cancer. Biochim. Biophys. Acta 1804(3), 559–566 (2010).
  Medline CASGoogle Scholar
• 31 Carey KD, Garton AJ, Romero MS et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66(16), 8163–8171 (2006).
  Medline CASGoogle Scholar
• 32 Beis I, Newsholme EA. The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates. Biochem. J. 152(1), 23–32 (1975).
  Medline CASGoogle Scholar
• 33 Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947–957 (2009).
  Medline CASGoogle Scholar
• 34 Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121–128 (2010).
  Medline CASGoogle Scholar
• 35 Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380–2388 (2010).
  Medline CASGoogle Scholar
• 36 Miller VA, Riely GJ, Zakowski MF et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J. Clin. Oncol. 26(9), 1472–1478 (2008).
  Medline CASGoogle Scholar
• 37 Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958–967 (2009).
  Medline CASGoogle Scholar
• 38 Sos ML, Koker M, Weir BA et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69(8), 3256–3261 (2009).
  Medline CASGoogle Scholar
• 39 Vivanco I, Rohle D, Versele M et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc. Natl Acad. Sci. USA 107(14), 6459–6464 (2010).
  Medline CASGoogle Scholar
• 40 Faber AC, Corcoran RB, Ebi H et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 1(4), 352–365 (2011).
  Medline CASGoogle Scholar
• 41 Ohashi K, Sequist LV, Arcila ME et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl Acad. Sci. USA 109(31), E2127–E2133 (2012).
  Medline CASGoogle Scholar
• 42 Ercan D, Xu CX, Yanagita M et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2(10), 934–947 (2012).
  Medline CASGoogle Scholar
• 43 Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039–1043 (2007).
  Medline CASGoogle Scholar
• 44 Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA 104(52), 20932–20937 (2007).
  Medline CASGoogle Scholar
• 45 Takezawa K, Pirazzoli V, Arcila ME et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR(T790M) mutation. Cancer Discov. 2(10), 922–933 (2012).
  Medline CASGoogle Scholar
• 46 Zhang ZF, Lee JC, Lin LP et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44(8), 852–860 (2012).
  Medline CASGoogle Scholar
• 47 Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3(75), 75ra26 (2011).
  MedlineGoogle Scholar
• 48 Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2(2), 117–125 (2002).
  Medline CASGoogle Scholar
• 49 Tamborini E, Bonadiman L, Greco A et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127(1), 294–299 (2004).
  Medline CASGoogle Scholar
• 50 Cools J, Deangelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348(13), 1201–1214 (2003).
  Medline CASGoogle Scholar
• 51 Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531), 876–880 (2001).
  Medline CASGoogle Scholar
• 52 Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl Acad. Sci. USA 102(21), 7665–7670 (2005). •• Demonstrates that irreversible EGFR inhibitors may overcome acquired resistance conferred by the gatekeeper T790M EGFR mutation.
  Medline CASGoogle Scholar
• 53 Yun CH, Mengwasser KE, Toms AV et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105(6), 2070–2075 (2008). • Discusses potential reasons for acquired resistance conferred by T790M EGFR mutation with biochemical and strutural analysis.
  Medline CASGoogle Scholar
• 54 Tsou HR, Overbeek-Klumpers EG, Hallett WA et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J. Med. Chem. 48(4), 1107–1131 (2005).
  Medline CASGoogle Scholar
• 55 Wissner A, Overbeek E, Reich MF et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. 46(1), 49–63 (2003).
  Medline CASGoogle Scholar
• 56 Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277(48), 46265–46272 (2002).
  Medline CASGoogle Scholar
• 57 Wong KK, Fracasso PM, Bukowski RM et al. A Phase I study with neratinib (HKI-272), an irreversible Pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin. Cancer Res. 15(7), 2552–2558 (2009).
  Medline CASGoogle Scholar
• 58 Sequist LV, Besse B, Lynch TJ et al. Neratinib, an irreversible Pan-ErbB receptor tyrosine kinase inhibitor: results of a Phase II trial in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28(18), 3076–3083 (2010).
  Medline CASGoogle Scholar
• 59 Gajiwala KS, Feng JL, Ferre R et al. Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure 21(2), 209–219 (2013).
  Medline CASGoogle Scholar
• 60 Janne PA, Schellens JH, Engelman JA et al. Preliminary activity and safety results from a Phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. Presented at: 2008 ASCO Annual Meeting. IL, USA, 30 May–3 June 2008.
  Google Scholar
• 61 Reckamp KL, Giaccone G, Camidge DR et al. A Phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small-cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 120(8), 1145–1154 (2014).
  Medline CASGoogle Scholar
• 62 Solca F, Dahl G, Zoephel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther. 343(2), 342–350 (2012).
  Medline CASGoogle Scholar
• 63 Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 28(25), 3965–3972 (2010).
  Medline CASGoogle Scholar
• 64 Miller VA, Hirsh V, Cadranel J. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a Phase 2b/3 randomised trial (vol 13, pg 528, 2012). Lancet Oncol. 13(5), E186–E186 (2012).
  Google Scholar
• 65 Katakami N, Atagi S, Goto K et al. LUX-Lung 4: a Phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. 31(27), 3335–3341 (2013).
  Medline CASGoogle Scholar
• 66 Yang JCH, Shih JY, Su WC et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a Phase 2 trial. Lancet Oncol. 13(5), 539–548 (2012).
  Medline CASGoogle Scholar
• 67 Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3327–3334 (2013).
  Medline CASGoogle Scholar
• 68 Besse B, Eaton KD, Soria JC et al. Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a Phase 2 trial in patients with advanced non-small-cell lung cancer. EJC Suppl. 6(12), 64–64 (2008).
  Google Scholar
• 69 Janne PA, Von Pawel J, Cohen RB et al. Multicenter, randomized, Phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J. Clin. Oncol. 25(25), 3936–3944 (2007).
  Medline CASGoogle Scholar
• 70 Zhou W, Ercan D, Chen L et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462(7276), 1070–1074 (2009). • Discovers WZ 4002, a mutant-selective irreversible EGFR inhibitor.
  Medline CASGoogle Scholar
• 71 Zhou WJ, Ercan D, Janne PA, Gray NS. Discovery of selective irreversible inhibitors for EGFR-T790M. Bioorg. Med. Chem. Lett. 21(2), 638–643 (2011).
  Medline CASGoogle Scholar
• 72 Walter AO, Sjin RTT, Haringsma HJ et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 3(12), 1404–1415 (2013). • Discovers CO-1686, a mutant-selective irreversible EGFR inhibitor.
  Medline CASGoogle Scholar
• 73 Sjin RTT, Lee K, Walter AO et al. In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing. Mol. Cancer Ther. 13(6), 1468–1479 (2014).
  Medline CASGoogle Scholar
• 74 Sequist LV, Soria JC, Gadgeel SM et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). Presented at: 2014 ASCO Annual Meeting. IL, USA, 30 May–3 June 2014.
  Google Scholar
• 75 Sequist LV, Soria JC, Goldman JW et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372(18), 1700–1709 (2015).
  MedlineGoogle Scholar
• 76 Ward RA, Anderton MJ, Ashton S et al. Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J. Med. Chem. 56(17), 7025–7048 (2013).
  Medline CASGoogle Scholar
• 77 Yosaatmadja Y, Silva S, Dickson JM et al. Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. J. Struct. Biol. 192(3), 539–544 (2015).
  Medline CASGoogle Scholar
• 78 Cross DAE, Ashton SE, Ghiorghiu S et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4(9), 1046–1061 (2014). • Discovers AZD-9291, a mutant-selective irreversible EGFR inhibitor.
  Medline CASGoogle Scholar
• 79 Finlay MRV, Anderton M, Ashton S et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 57(20), 8249–8267 (2014).
  Medline CASGoogle Scholar
• 80 Janne PA, Yang JCH, Kim DW et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372(18), 1689–1699 (2015).
  MedlineGoogle Scholar
• 81 Chang SH, Zhang LW, Xu SL et al. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine(790) -> methionine(790) mutant. J. Med. Chem. 55(6), 2711–2723 (2012).
  Medline CASGoogle Scholar
• 82 Xu SL, Zhang LW, Chang SH et al. Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine(790) -> methionine(790) mutant. Medchemcomm 3(9), 1155–1159 (2012).
  CASGoogle Scholar
• 83 Xu SL, Xu TF, Zhang LW et al. Design, synthesis, and biological evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties. J. Med. Chem. 56(21), 8803–8813 (2013).
  Medline CASGoogle Scholar
• 84 Xu TF, Zhang LW, Xu SL et al. Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine(790) to methionine(790) (T790M) mutants. Angew. Chem. Int. Edit. 52(32), 8387–8390 (2013).
  Medline CASGoogle Scholar
• 85 Xu TF, Peng T, Ren XM et al. C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR(T790M) mutant. Medchemcomm 6(9), 1693–1697 (2015).
  CASGoogle Scholar
• 86 Zhou W, Liu XF, Tu ZC et al. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant. J. Med. Chem. 56(20), 7821–7837 (2013).
  Medline CASGoogle Scholar
• 87 Wurz RP, Pettus LH, Ashton K et al. Oxopyrido[2,3-d]pyrimidines as covalent L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors. ACS Med. Chem. Lett. 6(9), 987–992 (2015).
  Medline CASGoogle Scholar
• 88 Qin MZ, Wang TT, Xu BX et al. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant. Eur. J. Med. Chem. 104, 115–126 (2015).
  Medline CASGoogle Scholar
• 89 Engel J, Richters A, Getlik M et al. Targeting drug resistance in EGFR with covalent inhibitors: a structure-based design approach. J. Med. Chem. 58(17), 6844–6863 (2015).
  Medline CASGoogle Scholar
• 90 Ercan D, Choi HG, Yun CH et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin. Cancer Res. 21(17), 3913–3923 (2015).
  Medline CASGoogle Scholar
• 91 Niederst MJ, Hu HC, Mulvey HE et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21(17), 3924–3933 (2015).
  Medline CASGoogle Scholar
• 92 Thress KS, Paweletz CP, Felip E et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small-cell lung cancer harboring EGFR T790M. Nat. Med. 21(6), 560–562 (2015). •• Discovers C797S EGFR mutation in patients who received AZD-9291 treatment and relapsed.
  Medline CASGoogle Scholar
• 93 Yu HA, Tian SK, Drilon AE et al. Acquired resistance of EGFR-Mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol. 1(7), 982–984 (2015). •• Discovers C797S EGFR mutation in patients who received AZD-9291 treatment and relapsed.
  MedlineGoogle Scholar
• 94 Bai F, Liu HY, Tong LJ et al. Discovery of novel selective inhibitors for EGFR-T790M/L858R. Bioorg. Med. Chem. Lett. 22(3), 1365–1370 (2012).
  Medline CASGoogle Scholar
• 95 Lee HJ, Schaefer G, Heffron TP et al. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov. 3(2), 168–181 (2013). • Demonstrates PKC-412 is a reversible, mutant-selective EGFR inhibitor.
  Medline CASGoogle Scholar
• 96 Taube E, Jokinen E, Koivunen P, Koivunen JP. A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance. Int. J. Cancer 131(4), 970–979 (2012).
  Medline CASGoogle Scholar
• 97 Hanan EJ, Eigenbrot C, Bryan MC et al. Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation. J. Med. Chem. 57(23), 10176–10191 (2014).
  Medline CASGoogle Scholar
• 98 Heald R, Bowman KK, Bryan MC et al. Noncovalent mutant selective epidermal growth factor receptor inhibitors: a lead optimization case study. J. Med. Chem. 58(22), 8877–8895 (2015).
  Medline CASGoogle Scholar
• 99 Bissantz C, Kuhn B, Stahl M. A medicinal chemist's guide to molecular interactions. J. Med. Chem. 53(14), 5061–5084 (2010).
  Medline CASGoogle Scholar